1/65
Looks like no tags are added yet.
substance use disorder
maladaptive pattern fo substance use leading to clinically significant impairment or distress, as manifested by ≥2 occurign within 12 month period
mila: 2-3
mod: 4-5
severe >6
substance use disorder- impaired control criteria
use of larger amnt, for longer than intended
craving
sig tiem spent obtining/using/recovering
repeated attempts to quit/control use
substance use disorder-social impairment criteria
social/interpersonal problems related to use
neglected major roel to use
acitivites given up for use
substance use disorder- cont use despite risk criteria
hazaroud use
physical/psych problems realted to use
substance use disorder- pharm criteria
tolerance
withdrawal
use disorder
longitudinal pattern of use despite neg consequences
intoxicaiton
reversible sub-specific syndrome encompassing acute effects after use
withdrawal
dev of substance specific sx after reduction/cessation
short term benefits of caffiene
increased mental alertness
improves in vigilance and reaction time
improved athletic performance
in mod doses, mitigates adverse effects of sleep dep and jet lag on cognitive performance and mental awareness
possible long term benefits of caffeine
dose dependent
assocaited with reduced risk of parkinson disease, alzheimer disease, alcoholic cirrhosis, and gout
mortality and caffeine
modest inverse relationshipo between coffee/tea consumption and all cause mortality
ADE of caffeine
high level consumption associated with dhort term aade
HA
anxiety
tremors
insomnia
chronic users ,less sensitive to adverse behavioral effects
long term, associated with GAD and SUD
caffeine intoxicaiton
recent consumption of caffeine (>250mg)
≥5 durign or shortly after use
restlessness, nervousness, insomnia, flushing, diuresis, GI disturbance, muscel twitching, rambling flow of though and speech, tachy/cardiac arrhythmia, psychomotor agitation
caffeine intoxication >1g
can produce ramblign speech, confused thinking, cardiac arrhythmias, marked agitation, tinnitusm and mild visual hallucinations
caffeine intoxicaiton >5-10g
can cause gran mal seizures
resp failure
death
caffeine withdrawal
prolonged daily use
abrupt cessation of or reduction in caffeine use followed within 24hr by 3+ of followign
HA- fatigue, dysmorphic mood, depressed, mood, or irritatbility; difficulty concentrating; flu like sx
onset 12-24hrs after last dose
resolves within 1 week
taper use instead to stopping abruptly
leading preventable cause of death
tobacco
tobacco neuropharm
psychoactive component of tobacco is nicotine
affects CNS by acting a an agonist to nicotoinic ACh receptors
reaches brain within 15sec
half life of nicotine is 2hrs
highly addictive- affects dopaminergic system
increased circulating norepi adn epi
increased release of vasopressin, beta- endoprhin, ACTH, adn cortisol, contribute to basic stimulatory effects
tobacco tolerance
disappearance tolerance: disappearance of nausea and dizziness after intake, more intense effect first use of the day
tobacco use disorder associated fts:
smokign within 30min of waking, smoking daily, increased number cig/day, and wakign at night to smoke
tobacco withdrawal criterion
daily use for at least several weeks
abrupt cessation of tobacco use, or reduction in amnt used followed within 24hrs of 4+:
irritability, frsustration,anger
anxierty
difficulty concentrating
increased appetite
restlessness
depressed mood
insomnia
can dev within 2 hrs of smokign last cig
peak in the first 24hrs to 48hrs and can last for weeks or months
other common sx of tobacco withdrawal
intesnse ccraving
drowsiness adn paradoxical trouble sleeping
decreased HR adn BP
decreased motor performance
increased muscle tension
tobacco use disorder tx- ready to quit
cmbine pharmacotherapy + behavioral support
first line med
varenciline
NRT
buproprion
behavioral interventions
brief counseling and motivational support
quitline referral
follow up 1-4weeks to assess adherence, SE, and response; reinfornce positice behavioral changes
varenicline
most effective singel modification
reduced cravings and nicotien reward
NRT
nicotine replacement therapy: combine short and long acting products (patch + gum/.lozenges)
tobacco use disorder-not ready to quit
motivational interviewing
reduce to quit strategy
set achieveable reduction oals
consider NRT or varenicline before quit date
continue engagements
offer follow up adn reasses readiness
avoid judgement or pressure
EVALI
acute lung injury associated with vaping
strongly linked to E acetate in THC containing prod
EVALI clinical pres
respiratory: dough, dyspnea, chest pain
GI: n/v/d, abd pain
constitutional: fever, chills, fatiguge; hypoxemia, tachy, adn tachypnea
EVALI dx
recent vaping exposure (within 90 days)
pulm infiltrates; eval for infection adn alternative dx
EVALI imaging
bilateral infiltrates on CXR or groufn glass opactities on CT
EVALI tx
stop vaping
supportive care and supp O2
consider systemic corticosteroids in selected cases after eval of infection
hosp is SpO2 <95% on RA, resp distress, ot sig comorbidities
cannabis use clinical fts
MC physical effects: dilation of conjunctival vessels and mild tachy
sx of acute intoxication are dose dependent adn include
tachy, BP changes, conjunctival injection, dry mouth, slowed or slurred speech, and ataxia
sedation and increased appetite
psych euphoria adn relaxaation
may cause acute depressionm anxiety, perceptual dist, transient paranoia
neuropsych impairement, esp attention, concentration, episodic memory, and associative learning
risk of death due to toxicity is neg
can be fatal due to taruamatic physical inury, or cardiac patho
cannabis comorbidities and adverse effects
substantial bidirectional comorbidity btwn cannabis use and psych disorders
use linked to decreased in goal directed activity adn decreased self efficacy known as amotivational syndrome → poor school/work performance
may be associated with higher a long term mortality rate: largely associated with accidents, suicide, and cardiopulm cond
cong function even while unintoxicated may become compromised, contributing to difficulty at school/work
adverse systemic effects of cannabis use
pulm and cards effects
hyper emesis syndrome
nonsemonima testicular cancer
association with cancer unclear
chronic use
esp in adolescence, assoicated with dev schizophrenia
cannabis intoxication
recent use
clinically sig problematic behavioral or psych changes (Impaired motor coordination, euphoria, anxiety, sensation of slowed time, impaired judegement, social withdrawal) tht dev due to use
≥2:
conj injection
increased appettite
dry mouth
tachy in high doses, iuses may experience depersonalization and derealizaiton
cannabis withdrawal
cessation of use that was heavy and prolonged
≥3 1week after d/c
irritablity, anger, aggression
nervousness or anxirty
sleep difficulty
decreased appetite or weight loss
restlessness
depressed mood
1+ physical sx causing discomfort
when is cannabis drug testing useful
when resuls help eval AMS, psychosis, co exposures
when relevent to DDx,
when required monitoring ot occupationa/legal purposes, with appropriate consent
drug test detection- single/occasional use
1-3days
drug test detection- moderate use
3-7 days
drug test detection- frequent/daily use
10-15 days
drug test detection- heavy chronic use
30+ days,
cannabis use disorder tx- brief intevention
pt centeres
nonjudgemental counseling
cannabis use disorder tx- psychosocial intervention
cog behavioral thearpy (CBT) and or motivational enhancement therapy
cannabis use disorder tx- addiction counseling and mutual help groups
marj ananymous
cannabis use disorder tx- med
limited benefit in reducign use
none are FDA approved
inhalants
volatile substances that produce rapid feeligns of euphoria and inebriation due to rapid absorption through pulm vascular bed
inhalants- clinical manifestations
often undetected
clues: chemical odor of breath, skin or clothes; empty solvent containers or bags, rags, ot gauze in possession or trash
huffer orglue sniffer rash: eczematoid dermatitis with erythema and pruritus in the peroral area, may extend to midface
inhalant intoxicaiton
rcent intended ot unintended short-term , high dise exposure to inhalant substances, including voaltile hydrocarbons such as toluene gasoline
clinically sig problematic behavioral or psych changes
2+
dizziness; nystagmus; incoordination; slurred speech; unsteady gait; laethargy; depressed reflexes; paychomotor retardation; tremor; generalized muscle weakness; blurred viison or diplopia
RARE
inhalant use eval
rapid bloos glucose
pulse ox
ECG an dcontinuous cardiac monitoring for arrythmias
urine drug screen
additional test if sus chronic inhalant misuse
methemeglobin level if nitrite misuse (very dark/chocolate brown venous blood or cyanosis even with O2)
venous blood lead if leaded gasoline misuse sus
CXR if hypoxemia, crackles,o rresp
inhalaatn use disorder tx- supportive care
supp 100% O2 by nonrebreather face mask for hypoxia
inhalant use disorder tx- antidotes
sepcific to exposure
methemaglobinemia caused by nitrite exposure (high dose oxygen + IV methylene blue)
llead toxicity (chelation)
nitrous oxide neurotox (vit B12)
inhalant use disorder tx- psych care
referral fro SUD tx adn or for formal detox
polydrug use an coexisting psychopathology are common
residentaial tx may improve outcome
stimulants
type so fpsychoactive substances that increase activity in rhe brain an dcan temp elevate alertness, mood, and awareness
amphetamine type substances usually taken orally, o rIV, methampheatomine also takedn intranasal
may be obtained by by Rx for tx of obesity, ADHD, and narcolepsy and diverted to illegal market
cocain powder ususalluy snorted or dissolved
stimulants- amphetamines neurophaarm
produce effects by releasing catecholamines, esp dopamine
newer cause mor release of norepi adn seritonin
tolerance dev, less addictive than cocaine
stimulants- cocaine neuropharm
behavioral effect is competitive blockade of dopamine reuptake
powergul addictive qualities
tolerance and psych dependence dev
physiological dependence occurs, withdrawal is usually mild
stimulant use- clinical manifestations
geenral- WL and malnutrition
dermatologic- skin sores adn excoriations, tracks
ENT- sinusitis, epistaaxis, performated nasal spetum, peridontal disease
resp- coughing, bronchitis, pneumonitis, pulm edema, resp distress, pneumothroax, pulm arterial HTN
CV- HTN, tachy, arrhytmias, and MI
neuro- seizures, HA, CVA, ICH, cog impairment
psych- impulsivity, anxiety, agitaiton, hallucinations, mood disturbacne, psychosis, paranoia
increased risk HIV and hep C with IVDU adn high risk sexual acitivty
stimulant intoxication
recent use of amphetamine type substanc, cocaine, or other stim
clinically sig problematic behavioral or psych changes that dev due to use
2+
tahcy or brady; ppupillary dialtion; hypo/.HTN; perspiration or chills; n/v; WL; depression, chest pain or cardiac arrhtymias
stimulant withdrawal
cessation or reduction in prolonged stimulant use
dysphoric mood and 2+ of following changes due to cesation
fatigue, vivid unpleasant dreams; insomniapr hypersomnia; increased appetite; psychomotor retardation or agitation
acute stimulant intoxication can cause
agitaiton
paranoia/psychosis
hyperthermia
tachy/HTN
ches pain/MI
arrhtyhmia
seizure
stroke
initial tx of acute stimulant intoxicaiton
supportive care
benzo for severe agitation/sympathetic sxcess
emergency eval for chest pain. hyperthermia, severe HTN, neuro findings
urien drug testing- cocaine
2-3days, 7 days with heavy use
detects metabolite- benzolycgonine; one of the most accutare DOA screenign
fals pos with coca tea, coca leaves
urine drug test- amphetamine/methamphetamine/MDMA/MDA/MDEA
1-2days, 2-4days with heavy use
numerous potential for false pos
urine drug testing- methylphenidate
not detected via amphetamine assay, needs targeted analysis
stimulant use disorder tx- psychosocial intervention
mild- indiviudal or gorup counseling; if no abstinence after 3 weeks transition to intensive outpt tx combined with contingency mgmt
mod- intensive outpt program combined with contingency mgmt and motivational interviewing
subsequent tx- for indiv who respond to psychosocial tx, cont tx fro up to one year; return to tx for return to use
stimulant use disorder- suboptimal response after 8-12weeks
consider pharm augmentation
cocaine use- topiramate first choice; then long acting amphetamines, then combo
methmphetamine use- comboof naltrexone and bupropion as the first choice; mirtazapien adn methylphenidate are aother tx options